UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies

Mark P. Lythgoe(Hammersmith Hospital), Sarah P. Blagden(Churchill Hospital), Richard Sullivan(Precision Spine (United States))

The Lancet Oncology

August 29, 2023

10.1016/s1470-2045(23)00218-8

Cited by 5

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

The Lancet Commission on diagnostics: transforming access to diagnostics

|The Lancet|2021|442

Sustainable care for children with cancer: a Lancet Oncology Commission

|The Lancet Oncology|2020|346

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222